CD274 and breast carcinoma: Additionally, an exploratory biomarker analysis from the CheckMate-7FL trial, presented at the San Antonio Breast Cancer Symposium 2023, provided evidence supporting the efficacy of nivolumab in combination with NAC based not only on PD-L1 status, a well-established immune marker, but also on stromal tumor-infiltrating lymphocytes (sTIL) levels.